Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron (NASDAQ: LGVN) will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference call number: 1.877.407.0789 with Conference ID 13759888. A replay will be available in the Events & Presentations section of the company website following the call.
Longeveron (NASDAQ: LGVN) announced that China Patent No. 2026031300230720, entitled “Potency Assay,” was granted by the China National Intellectual Property Administration and provides patent protection in China through 2041 assuming annuity fees are paid.
This patent covers potency assay methods for assessing human mesenchymal stem cells (MSCs) from multiple tissue sources and expands Longeveron’s international portfolio to 52 patents. The company is also advancing a Phase 2b HLHS trial with results expected in Q3 2026, which could support a U.S. BLA depending on outcomes.
Longeveron (NASDAQ: LGVN) reported 2025 results and a business update on March 17, 2026. Revenues fell 50% to $1.2M; net loss widened to $22.7M. The company closed an initial $15M private placement (up to $30M) and expects pivotal Phase 2b ELPIS II HLHS topline results in Q3 2026.
Management plans partnering strategies, expects a potential BLA path for HLHS if ELPIS II is successful, and projects cash runway into Q4 2026 after the transaction.
Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. An archived replay will be available on the company website under Events & Presentations.
Longeveron (NASDAQ: LGVN) closed an initial tranche of a private placement on March 11, 2026, raising approximately $15 million upfront, with eligibility for an additional ~$15 million tied to milestone conditions from its Phase 2b ELPIS II HLHS trial. The financing was priced at-the-market under Nasdaq rules and led by Coastlands Capital with participation from Janus Henderson and other healthcare funds. The company issued 6,013,384 Class A shares at $0.52 and Series A non-voting convertible preferred shares convertible into 22,832,770 Class A shares at $0.52. Net proceeds are expected to extend the cash runway into 4Q26, past the anticipated 3Q26 topline readout, and the company sold investors rights to 50% of net proceeds from any future Rare Pediatric Disease Priority Review Voucher receipt for its laromestrocel HLHS program.
Longeveron (NASDAQ: LGVN) entered a private placement expected to raise up to $30 million in gross proceeds, with an initial closing of approximately $15 million priced at-the-market under Nasdaq rules.
Initial proceeds fund operations into 4Q2026, past anticipated pivotal Phase 2b ELPIS II HLHS topline data in 3Q2026. The financing includes Class A shares and Series A non-voting convertible preferred shares convertible at $0.52, and a contingent second tranche tied to trial milestones and share price.
Longeveron (NASDAQ: LGVN) reported Phase 2b results published in Cell Stem Cell showing intravenous laromestrocel improved physical condition in 148 ambulatory patients with age-related frailty versus placebo. 6-minute walk test (6MWT) increased by 63.4m at month 9 (95% CI: 17.1–109.6m; p=0.0077). Findings include dose-response signals and a potential TIE-2 biomarker for responsiveness.
Longeveron (NASDAQ: LGVN) appointed Stephen H. Willard as CEO, effective February 11, 2026, replacing interim CEO Than Powell who will assist the transition and continue business development work.
The company is focused on top-line Phase 2b HLHS results expected in Q3 2026; FDA guidance indicated a successful trial could serve as a pivotal study for a BLA.
Longeveron (NASDAQ: LGVN) applauds Congress passing the Mikaela Naylon Give Kids a Chance Act, which reauthorizes the Rare Pediatric Disease Priority Review Voucher (PPRV) Program and extends voucher eligibility for medicines approved by the FDA before September 30, 2029.
The company noted FDA Rare Pediatric Disease, Orphan Drug and Fast Track designations for its laromestrocel program in Hypoplastic Left Heart Syndrome (HLHS). The Phase 2b ELPIS II trial enrolled 40 pediatric patients at 12 centers, with top-line results anticipated in Q3 2026. Since 2024, PRVs have traded for $150–200 million each.
Longeveron (NASDAQ: LGVN) announced that the Japan Patent Office granted Japan Patent No. 2022-563984 for potency assay methods to assess human mesenchymal stem cells (MSCs), with protection through April 20, 2041 assuming annuity payments.
The patent expands Longeveron's international IP to 33 issued patents and supports development of laromestrocel (Lomecel-B). A pivotal Phase 2b trial in Hypoplastic Left Heart Syndrome (HLHS) is ongoing, with results expected in Q3 2026, which may enable a U.S. BLA submission depending on outcomes.